NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

Clinical trial NCT07563829 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07563829
Sponsor: NextPoint Therapeutics, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Malignant Neoplasm

Start date: 2026-04-01
Primary completion: 2027-04-01
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.